Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

Abstract: Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.

Abstract: The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

Abstract: A method of producing aluminum chlorohydrate comprises adding small form aluminum metal pellets to a reactant receiving space of a reactor tank to form a pellet bed; adding aqueous hydrochloric acid to the reactant receiving space of the reactor tank; and continuously circulating the aqueous hydrochloric acid through the pellet bed. In some embodiments, the continuously circulating aqueous hydrochloric acid dispels reaction gases from the pellet bed. Methods described herein can, in some cases, further comprise consecutively adding additional small form aluminum metal pellets to the reactant receiving space of the reactor tank as the small form aluminum metal pellets are consumed in the pellet bed.

Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.

Abstract: The present invention includes a system, kit and apparatus to aid in the realignment of one or more bones of a patient. The present invention provides a substantially rigid orthopedic stabilization scaffold for attachment of one or more external fixators for the realignment of one or more bones of a patient. The orthopedic stabilization scaffold includes a first anchorable frame and a second anchorable frame that are removably attachable to an operating table and connected adjustably by one or more crossbars.

Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease encompassing chronic bronchitis, emphysema and remodeling of small airways that can be treated by the caveolin-1 peptide CSP7 (SEQ ID NO:1). Chronic tobacco smoke exposure (TSE)-induced lung injury includes increased alveolar and airway inflammation, type II alveolar epithelial cells (A2Cs) senescence and apoptosis, and mucus hypersecretion by AECs. Interleukin 17A-mediated induction of plasminogen activator inhibitor-1 (PAI-1) expression through caveolin-1 led to TSE-induced lung injury, which was abrogated by CSP7 treatment which abolished A2Cs senescence and apoptosis, and AECs mucus hypersecretion in TSE wild type (WT) mice. Ex vivo CSP7 treatment of lung tissue of COPD patients decreased A2C apoptosis and AEC mucus hypersecretion. Lung injury induced by PAI-1 expression in COPD lung tissue and WT mice (20 weeks TSE), with A2Cs senescence and apoptosis, and AEC mucus hypersecretion was abolished by CSP7.

Abstract: Provided herein are methods for the treatment of pancreatitis and/or the prevention of pancreatic cancer. The treatment may comprise the administration of an inducer of acinar-to-ductal metaplasia (ADM), such as an agonist of the mitogen-activated protein kinase (MAPK) signaling pathway, such as a BRAF inhibitor, or an epigenetic modifier, such as a bromodomain extra-terminal motif (BET) inhibitor.

Abstract: DNA is sequenced by (a) independently sequencing first and second strands of a dsDNA to obtain corresponding first and second sequences; and (b) combining the first and second sequences to generate a consensus sequence of the dsDNA. By independently sequencing first and second strands the error probability of the consensus sequence approximates a multiplication of those of the first and second sequences.

Abstract: Methods and devices for the prevention, treatment and diagnosis of cancer include assessing and quantifying imperfect dsDNA break repair. The methods may include determining a deletion signal for a DNA-containing sample of a subject, wherein the deletion signal comprises distributions of deletions (frequencies) of deletions with microhomologies of different lengths at the deletion sites in a DNA sequence or genome of the subject or sample thereof. The method may further include decomposing the deletion signal into components corresponding to changes arising from: (1) DNA repair processes, (2) systematic effects due to mapping personal deletion variants to reference genomes, and (3) false positive deletions generated during sample preparation, sequencing, and analysis, and quantifying these components to produce mutational signatures of defective HRR.

Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize cancer testis (CT) antigens of the MAGE-A4 antigen. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.

Abstract: Pressure modulating soft actuator array devices and related systems and methods. One example of the present systems comprises: a device having a body that defines a plurality of cavities; a pressure source configured to be in fluid communication with the plurality of cavities; a plurality of sensors configured to capture data indicative of pressure within the plurality of cavities; and one or more controllers configured to actuate the pressure source to move fluid toward and/or away from one or more of the plurality of cavities in response to data captured by the plurality of sensors; wherein the device is configured to be disposed between a user and a surface on which the user is seated upon.

Abstract: Certain aspects are directed to a housing and cap to provide protection of medical devices having one or more percutaneous connection (e.g., a three-way stopcock or catheter port).

Abstract: Certain embodiments are directed to adenosine receptor antagonists that inhibit migration and growth of cancer cells.

Abstract: The present disclosure provides pharmaceutical compositions which exhibit improved flowability as measured by the angle of repose. The pharmaceutical compositions comprise an active pharmaceutical ingredient, two or more absorbents, and optionally surfactant. These pharmaceutical compositions may be used in the manufacturing of pharmaceutical dosage forms or an additive manufacturing process such as 3D selective laser sintering printing.

Abstract: Provided herein are CD79b antibodies and CD79b-specific chimeric antigen receptors (CARs). Further provided herein are immune cells expressing the CD79b-specific CARs and methods of treating cancer by administering the CD79b-specific CAR immune cells.

Abstract: The current disclosure provides for novel therapeutic methods by identifying cancer patient populations that may be treated effectively by immunotherapies. Accordingly, aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after the subject has been determined to have increased expression of CXCL13 in a biological sample from the subject.